Nevertheless, in line with the common role of anti-apoptotic Bcl-2 family members in cancer resistance to cytotoxic therapy [37, 38] we find that Bcl-xL inhibition can sensitize osteosarcoma cells to low dose chemotherapy. This evidence concerns the gene BCL2L1 and osteosarcoma.